Selective aryl hydrocarbon receptor modulator-mediated repression of CD55 expression induced by cytokine exposure

Journal of Pharmacology and Experimental Therapeutics

Volumn 342, Issue 2, 2012, Pages 345-355

  Narayanan, Gitanjali A ^a   Murray, Iain A ^a   Krishnegowda, Gowdahalli ^b   Amin, Shantu ^b   Perdew, Gary H ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3',4' DIMETHOXY ALPHA NAPHTHOFLAVONE; AROMATIC HYDROCARBON RECEPTOR; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; CYTOKINE; DECAY ACCELERATING FACTOR; IMMUNOMODULATING AGENT; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ARTICLE; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CELL PROTECTION; CELL SURFACE; COMPLEMENT DEPOSITION; CONTROLLED STUDY; CYTOLYSIS; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME METABOLISM; ENZYME REPRESSION; HOST CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOSURVEILLANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; REGULATORY MECHANISM; TUMOR CELL; TUMOR MICROENVIRONMENT;

ANTIGENS, CD46; ANTIGENS, CD55; BENZOFLAVONES; CELL LINE, TUMOR; COMPLEMENT C3; CYTOKINES; HUMANS; INTERLEUKIN-1BETA; PROMOTER REGIONS, GENETIC; RECEPTORS, ARYL HYDROCARBON; RNA, MESSENGER;

EID: 84864143110     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.193482     Document Type: Article

References (41)

1. Ahmed S, Valen E, Sandelin A, and Matthews J (2009) Dioxin increases the interaction between aryl hydrocarbon receptor and estrogen receptor α at human promoters. Toxicol Sci 111:254-266.
2. Andoh A, Kinoshita K, Rosenberg I, and Podolsky DK (2001) Intestinal trefoil factor induces decay-accelerating factor expression and enhances the protective activities against complement activation in intestinal epithelial cells. J Immunol 167:3887-3893. (Pubitemid 32910833)
3. Barhoover MA, Hall JM, Greenlee WF, and Thomas RS (2010) Aryl hydrocarbon receptor regulates cell cycle progression in human breast cancer cells via a functional interaction with cyclin-dependent kinase 4. Mol Pharmacol 77:195-201.
4. Beischlag TV, Luis Morales J, Hollingshead BD, and Perdew GH (2008) The aryl hydrocarbon receptor complex and the control of gene expression. Crit Rev Eukaryot Gene Expr 18:207-250. (Pubitemid 351620286)
5. Durrant LG, Chapman MA, Buckley DJ, Spendlove I, Robins RA, and Armitage NC (2003) Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients. Cancer Immunol Immunother 52:638-642. (Pubitemid 37268197)
6. Ewulonu UK, Ravi L, and Medof ME (1991) Characterization of the decayaccelerating factor gene promoter region. Proc Natl Acad Sci U S A 88:4675-4679. (Pubitemid 21914604)
7. Fishelson Z, Donin N, Zell S, Schultz S, and Kirschfink M (2003) Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 40:109-123. (Pubitemid 36959821)
8. Fujita T, Inoue T, Ogawa K, Iida K, and Tamura N (1987) The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb. J Exp Med 166:1221-1228. (Pubitemid 18051418)
9. Funatake CJ, Marshall NB, and Kerkvliet NI (2008) 2,3,7,8- Tetrachlorodibenzo-pdioxin alters the differentiation of alloreactive CD8+ T cells toward a regulatory T cell phenotype by a mechanism that is dependent on aryl hydrocarbon receptor in CD4+ T cells. J Immunotoxicol 5:81-91. (Pubitemid 351431256)
10. Holla VR, Wang D, Brown JR, Mann JR, Katkuri S, and DuBois RN (2005) Prostaglandin E2 regulates the complement inhibitor CD55/decay-accelerating factor in colorectal cancer. J Biol Chem 280:476-483. (Pubitemid 40165012)
11. Ikeda J, Morii E, Liu Y, Qiu Y, Nakamichi N, Jokoji R, Miyoshi Y, Noguchi S, and Aozasa K (2008) Prognostic significance of CD55 expression in breast cancer. Clin Cancer Res 14:4780-4786.
12. Kewley RJ, Whitelaw ML, and Chapman-Smith A (2004) The mammalian basic helix-loop-helix/PAS family of transcriptional regulators. Int J Biochem Cell Biol 36:189-204. (Pubitemid 37487755)
13. Kim DD and Song WC (2006) Membrane complement regulatory proteins. Clin Immunol 118:127-136. (Pubitemid 43199649)
14. Kimura A, Naka T, Nohara K, Fujii-Kuriyama Y, and Kishimoto T (2008) Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells. Proc Natl Acad Sci U S A 105:9721-9726. (Pubitemid 352031367)
15. Li L, Spendlove I, Morgan J, and Durrant LG (2001) CD55 is over-expressed in the tumour environment. Br J Cancer 84:80-86. (Pubitemid 32102508)
16. Liu J, Miwa T, Hilliard B, Chen Y, Lambris JD, Wells AD, and Song WC (2006) The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. J Exp Med 201:567-577. (Pubitemid 40289547)
17. Loberg RD, Day LL, Dunn R, Kalikin LM, and Pienta KJ(2006) Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo. Neoplasia 8:69-78.
18. Lublin DM and Atkinson JP (1989) Decay accelerating factor: biochemistry, molecular biology, and function. Annu Rev Immunol 7:35-58. (Pubitemid 19138006)
19. Markwell MA (1982) A new solid-state reagent to iodinate proteins. I. Conditions for the efficient labeling of antiserum. Anal Biochem 125:427-432. (Pubitemid 13219791)
20. Medof ME, Kinoshita T, and Nussenzweig V (1984) Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med 160:1558-1578. (Pubitemid 15220783)
21. Meyer BK, Pray-Grant MG, Vanden Heuvel JP, and Perdew GH (1998) Hepatitis B virus X-associated protein 2 is a subunit of the unliganded aryl hydrocarbon receptor core complex and exhibits transcriptional enhancer activity. Mol Cell Biol 18:978-988. (Pubitemid 28063432)
22. Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, and Bradfield CA (2010) An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol 185:3190-3198.
23. Murray IA, Flaveny CA, Chiaro CR, Sharma AK, Tanos RS, Schroeder JC, Amin SG, Bisson WH, Kolluri SK, and Perdew GH (2011) Suppression of cytokine-mediated complement factor gene expression through selective activation of the Ah receptor with 3′,4′-dimethoxy-α-naphthoflavone. Mol Pharmacol 79:508-519.
24. Murray IA, Krishnegowda G, DiNatale BC, Flaveny C, Chiaro C, Lin JM, Sharma AK, Amin S, and Perdew GH (2010a) Development of a selective modulator of aryl hydrocarbon (Ah) receptor activity that exhibits anti-inflammatory properties. Chem Res Toxicol 23:955-966.
25. Murray IA, Morales JL, Flaveny CA, Dinatale BC, Chiaro C, Gowdahalli K, Amin S, and Perdew GH (2010b) Evidence for ligand-mediated selective modulation of aryl hydrocarbon receptor activity. Mol Pharmacol 77:247-254.
26. Niehans GA, Cherwitz DL, Staley NA, Knapp DJ, and Dalmasso AP (1996) Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am J Pathol 149:129-142. (Pubitemid 26230985)
27. Oft M, Heider KH, and Beug H (1998) TGFβ signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol 8:1243-1252. (Pubitemid 28540052)
28. Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, Weller M, et al. (2011) An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478:197-203.
29. Patel RD, Murray IA, Flaveny CA, Kusnadi A, and Perdew GH (2009) Ah receptor represses acute-phase response gene expression without binding to its cognate response element. Lab Invest 89:695-707.
30. Perdew GH (1988) Association of the Ah receptor with the 90-kDa heat shock protein. J Biol Chem 263:13802-13805.
31. Ramirez JM, Brembilla NC, Sorg O, Chicheportiche R, Matthes T, Dayer JM, Saurat JH, Roosnek E, and Chizzolini C (2010) Activation of the aryl-hydrocarbon receptor reveals distinct requirements for IL-22 and IL-17 production by human T helper cells. Eur J Immunol 40:2450-2459.
32. Reyes H, Reisz-Porszasz S, and Hankinson O (1992) Identification of the Ah receptor nuclear translocator protein (Arnt) as a component of the DNA binding form of the Ah receptor. Science 256:1193-1195.
33. Riley-Vargas RC, Gill DB, Kemper C, Liszewski MK, and Atkinson JP (2004) CD46: expanding beyond complement regulation. Trends Immunol 25:496-503. (Pubitemid 39490257)
34. Smith KJ, Murray IA, Tanos R, Tellew J, Boitano AE, Bisson WH, Kolluri SK, Cooke MP, and Perdew GH (2011) Identification of a high-affinity ligand that exhibits complete aryl hydrocarbon receptor antagonism. J Pharmacol Exp Ther 338:318-327.
35. Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, and Koki AT (2000) COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89:2637-2645. (Pubitemid 32011609)
36. Spiller OB, Criado-García O, Rodríguez De Córdoba S, and Morgan BP (2000) Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack. Clin Exp Immunol 121:234-241. (Pubitemid 30659759)
37. Vogel CF and Matsumura F (2009) A new cross-talk between the aryl hydrocarbon receptor and RelB, a member of the NF-κB family. Biochem Pharmacol 77:734-745.
38. Vogel CF, Sciullo E, and Matsumura F (2004) Activation of inflammatory mediators and potential role of ah-receptor ligands in foam cell formation. Cardiovasc Toxicol 4:363-373. (Pubitemid 39552105)
39. Walport MJ (2001) Complement. First of two parts. N Engl J Med 344:1058-1066.
40. Whaley K and SchwaebleW(1997) Complement and complement deficiencies. Semin Liver Dis 17:297-310. (Pubitemid 27527654)
41. Zipfel PF and Skerka C (2009) Complement regulators and inhibitory proteins. Nat Rev Immunol 9:729-740.